S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
Log in

NASDAQ:AVEOAVEO Pharmaceuticals Stock Price, Forecast & News

$4.40
+0.06 (+1.38 %)
(As of 08/13/2020 04:00 PM ET)
Add
Compare
Today's Range
$4.26
Now: $4.40
$4.51
50-Day Range
$4.16
MA: $4.66
$5.70
52-Week Range
$2.23
Now: $4.40
$11.20
Volume316,300 shs
Average Volume519,078 shs
Market Capitalization$70.76 million
P/E RatioN/A
Dividend YieldN/A
Beta1.53
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC). The company has also completed a Phase 3 TIVO-3 trial of tivozanib for the treatment of RCC; and initiated enrollment in a phase Ib/II clinical trial of tivozanib in combination with Opdivo (nivolumab), an immune checkpoint (PD-1) inhibitor, for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent hepatocyte growth factor inhibitory antibody for the treatment of squamous cell carcinoma of the head and neck, metastatic pancreatic ductal cancer, and acute myeloid leukemia; and AV-203, a potent anti-ErbB3 specific monoclonal antibody, which has completed Phase I clinical trial for treating esophageal cancer. The company's preclinical stage products include AV-380, a potent humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and AV-353 for the treatment of pulmonary arterial hypertension. It has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec; and Kyowa Hakko Kirin Co., Ltd. AVEO Pharmaceuticals, Inc. has a clinical collaboration with AstraZeneca PLC to evaluate IMFINZI (durvalumab), a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1). The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.
Read More
AVEO Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.82 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:AVEO
CUSIP05358810
Phone617-588-1960

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$28.80 million
Cash Flow$0.55 per share
Book Value$0.92 per share

Profitability

Net Income$9.39 million

Miscellaneous

Employees17
Market Cap$70.76 million
Next Earnings Date11/10/2020 (Estimated)
OptionableOptionable
$4.40
+0.06 (+1.38 %)
(As of 08/13/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AVEO News and Ratings via Email

Sign-up to receive the latest news and ratings for AVEO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











AVEO Pharmaceuticals (NASDAQ:AVEO) Frequently Asked Questions

How has AVEO Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

AVEO Pharmaceuticals' stock was trading at $3.49 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AVEO shares have increased by 26.1% and is now trading at $4.40.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of AVEO Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AVEO Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for AVEO Pharmaceuticals
.

When is AVEO Pharmaceuticals' next earnings date?

AVEO Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for AVEO Pharmaceuticals
.

How were AVEO Pharmaceuticals' earnings last quarter?

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) announced its earnings results on Monday, August, 10th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.09. AVEO Pharmaceuticals had a negative return on equity of 27.47% and a negative net margin of 13.28%.
View AVEO Pharmaceuticals' earnings history
.

When did AVEO Pharmaceuticals' stock split? How did AVEO Pharmaceuticals' stock split work?

AVEO Pharmaceuticals's stock reverse split on the morning of Thursday, February 20th 2020. The 1-10 reverse split was announced on Wednesday, February 19th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 19th 2020. An investor that had 100 shares of AVEO Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for AVEO?

5 analysts have issued 1-year target prices for AVEO Pharmaceuticals' shares. Their forecasts range from $7.00 to $26.00. On average, they anticipate AVEO Pharmaceuticals' stock price to reach $17.80 in the next year. This suggests a possible upside of 304.5% from the stock's current price.
View analysts' price targets for AVEO Pharmaceuticals
.

What are Wall Street analysts saying about AVEO Pharmaceuticals stock?

Here are some recent quotes from research analysts about AVEO Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "AVEO got a huge boost from the approval of Fotivda in Europe for the first-line treatment of advanced renal cell carcinoma (RCC). The company receives royalties from Fotivda sales in certain European countries. This is another revenue driver. In March 2020, AVEO submitted a new drug application (NDA) to the FDA for Fotivda to treat RCC. In June the FDA accepted the NDA and set an action date of Mar 31, 2021. A potential approval will be a huge impetus for the company as well as the drug’s sales in the future quarters. However, if the final analysis yields an OS hazard ratio of more than 1, AVEO will withdraw its NDA for Fotivda. Such delays will be detrimental to growth. Failure to receive regulatory nods or termination of any deal will significantly hurt the stock ahead. Shares have underperformed the industry year to date." (8/10/2020)
  • 2. HC Wainwright analysts commented, "We raise our rating on AVEO to and increase our 12-month price target to $1.75 per share. We derive our price target based on a risk-adjusted NPV analysis of projected tivozanib and ficlatuzumab revenues through 2030, assuming a 12.0% discount rate and a 0% terminal growth rate. We derive an rNPV of $393M for the products and add in pro forma net cash and cash equivalents of $65.2M to arrive at a 12-month price target of $1.75 per share. (1) clinical; (2) commercial; (3) financial; (4) partnership; and (5) intellectual property." (9/11/2019)

Has AVEO Pharmaceuticals been receiving favorable news coverage?

News coverage about AVEO stock has trended extremely negative on Thursday, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. AVEO Pharmaceuticals earned a coverage optimism score of -4.1 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future.
View the latest news about AVEO Pharmaceuticals
.

Are investors shorting AVEO Pharmaceuticals?

AVEO Pharmaceuticals saw a increase in short interest during the month of June. As of June 15th, there was short interest totaling 2,010,000 shares, an increase of 16.9% from the May 31st total of 1,720,000 shares. Based on an average daily trading volume, of 806,400 shares, the days-to-cover ratio is presently 2.5 days. Approximately 9.1% of the company's shares are short sold.
View AVEO Pharmaceuticals' Short Interest
.

Who are some of AVEO Pharmaceuticals' key competitors?

What other stocks do shareholders of AVEO Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AVEO Pharmaceuticals investors own include Advanced Micro Devices (AMD), Exelixis (EXEL), Inovio Pharmaceuticals (INO), Micron Technology (MU), Opko Health (OPK), Novavax (NVAX), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE), NVIDIA (NVDA) and Amarin (AMRN).

Who are AVEO Pharmaceuticals' key executives?

AVEO Pharmaceuticals' management team includes the following people:
  • Mr. Michael P. Bailey, CEO, Pres & Director (Age 54)
  • Ms. Karuna Rubin, Sr. VP & Gen. Counsel (Age 42)
  • Dr. Michael N. Needle, Chief Medical Officer (Age 59)
  • Dr. Nikhil Mehta Ph.D., Sr. VP of Regulatory & Quality Assurance (Age 60)
  • Dr. Emile Farhan Ph.D., VP of Technical Operations

What is AVEO Pharmaceuticals' stock symbol?

AVEO Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVEO."

Who are AVEO Pharmaceuticals' major shareholders?

AVEO Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include NEA Management Company LLC (24.58%), Monashee Investment Management LLC (1.55%), Goldman Sachs Group Inc. (0.45%), WINTON GROUP Ltd (0.29%), Bank of New York Mellon Corp (0.26%) and Strs Ohio (0.25%). Company insiders that own AVEO Pharmaceuticals stock include Anthony B Evnin, Equity Opportunities Fu Growth, Equity Opportunities Iv Growth, Michael P Bailey, Peter J Barris and Peter W Sonsini.
View institutional ownership trends for AVEO Pharmaceuticals
.

Which major investors are selling AVEO Pharmaceuticals stock?

AVEO stock was sold by a variety of institutional investors in the last quarter, including WINTON GROUP Ltd.
View insider buying and selling activity for AVEO Pharmaceuticals
.

Which major investors are buying AVEO Pharmaceuticals stock?

AVEO stock was acquired by a variety of institutional investors in the last quarter, including NEA Management Company LLC, Monashee Investment Management LLC, Goldman Sachs Group Inc., Bank of New York Mellon Corp, Strs Ohio, Marshall Wace North America L.P., New York State Common Retirement Fund, and Wedbush Securities Inc.. Company insiders that have bought AVEO Pharmaceuticals stock in the last two years include Anthony B Evnin, Equity Opportunities Fu Growth, Equity Opportunities Iv Growth, Michael P Bailey, Peter J Barris, and Peter W Sonsini.
View insider buying and selling activity for AVEO Pharmaceuticals
.

How do I buy shares of AVEO Pharmaceuticals?

Shares of AVEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AVEO Pharmaceuticals' stock price today?

One share of AVEO stock can currently be purchased for approximately $4.40.

How big of a company is AVEO Pharmaceuticals?

AVEO Pharmaceuticals has a market capitalization of $70.76 million and generates $28.80 million in revenue each year. The biopharmaceutical company earns $9.39 million in net income (profit) each year or $0.61 on an earnings per share basis. AVEO Pharmaceuticals employs 17 workers across the globe.

What is AVEO Pharmaceuticals' official website?

The official website for AVEO Pharmaceuticals is www.aveooncology.com.

How can I contact AVEO Pharmaceuticals?

AVEO Pharmaceuticals' mailing address is ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-588-1960 or via email at [email protected]

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.